SAGE Therapeutics (SAGE) : acquisition proposal from Biogen (BIIB)

• SAGE Therapeutics (SAGE) was acquired by Supernus Pharma (SUPN). (31 Jul 2025)

 

 

 

 

  

 

 

SAGE Therapeutics confirms receipt of acquisition proposal from Biogen (BIIB) 

• Sage Therapeutics, Inc. (SAGE) confirmed that Biogen Inc. (BIIB) has submitted to the Company an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share.
• Consistent with its fiduciary duties and in consultation with its independent financial and legal advisors, the Sage Board of Directors will carefully review and evaluate the proposal made by Biogen to determine the course of action that it believes is in the best interest of the Company and all Sage shareholders.

Supernus Pharma (SUPN) reported earnings on Mon 7 May 2018 (a/h)

** charts 2 days after earnings **

 

ROCKVILLE, Md. (AP) _ Supernus Pharmaceuticals Inc. (SUPN) on Tuesday reported first-quarter profit of $26.4 million.

On a per-share basis, the Rockville, Maryland-based company said it had net income of 49 cents.

The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of 33 cents per share.

The drugmaker posted revenue of $90.4 million in the period, also exceeding Street forecasts. Four analysts surveyed by Zacks expected $88.2 million.

Supernus shares have increased 12 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $44.65, a rise of 40 percent in the last 12 months.